ARYx’s RetroMetabolic Drug Design™ (ARM) technology allows the company many opportunities for blockbuster development and commercialization. We are building intellectual property in the following areas, to be pursued further as appropriate.

Preclinical Development Programs

We are currently pursuing two late stage discovery programs, ATI-20,000 and ATI-24,000, which focus on metabolic and gastrointestinal disorders, respectively. We have identified potent pharmacologically active compounds in each of these programs. In addition to these two active discovery programs, we have a number of additional feasibility programs which we believe will continue to provide future research and development programs for us.